Techno Drugs Embarks on Restructuring Plan with Tk50cr Bond Issue

Techno Drugs Limited, a prominent player in the pharmaceutical industry, has announced plans to issue a coupon-bearing bond worth Tk50 crore. This strategic move aims to restructure the company's high-cost bank loans, which have been a significant burden on its financials. The decision, approved at the company's recent board meeting, is subject to shareholder approval at an extraordinary general meeting (EGM) scheduled for June 24 and clearance from the Bangladesh Securities and Exchange Commission (BSEC).

The proposed five-year bond will be structured as 25% redeemable and 75% convertible, with MTB Capital Limited appointed as the issue manager and arranger. According to Company Secretary SM Abu Talha Siddik, the primary objective of the bond is to efficiently manage the company's high-cost bank liabilities. This initiative comes at a critical juncture for Techno Drugs, as it faces declining profits and a sharp rise in long-term debt.

One Bank PLC has recently filed a case in the Money Loan Court against the company and its directors to recover defaulted loans worth around Tk150 crore. The court has issued a public notice summoning the directors in connection with the case. In response to the legal dispute, Siddik stated that the company is in discussions with the bank and hopes for a swift resolution. Despite the challenges, Techno Drugs remains committed to its growth strategy, having raised Tk100 crore through an initial public offering (IPO) under the book-building method in 2024.

Audit reports reveal that a significant portion of the IPO proceeds was utilized for machinery acquisition and construction at the company's Narsingdi and Gazipur facilities. Additionally, Tk30 crore was used to partially repay bank loans, including Tk25 crore to One Bank and smaller amounts to other financial institutions. However, the company's financial position has weakened further in FY26, with revenue declining 11% year-on-year to Tk232 crore and net profit falling 16% to Tk15.54 crore.

The surge in long-term loans to Tk239.56 crore by the end of March 2026, marking a 54% increase compared to the same period last year, has added to the company's financial woes. The bond issue is expected to help alleviate some of these pressures, enabling Techno Drugs to better navigate the complexities of the pharmaceutical industry. As the company moves forward with its restructuring plan, it is essential to closely monitor the outcome of the EGM and the subsequent regulatory approvals.

In the context of the broader pharmaceutical industry, the challenges faced by Techno Drugs are not unique. Many companies in the sector are grappling with similar issues, including high-cost debt and declining profits. The ability of Techno Drugs to successfully restructure its debt and improve its financial performance will be closely watched by industry observers and stakeholders.

The issuance of the Tk50 crore bond is a critical step in this process, and its success will depend on various factors, including the company's ability to secure shareholder approval and regulatory clearance. As the pharmaceutical industry continues to evolve, companies like Techno Drugs must adapt and innovate to remain competitive. The outcome of this restructuring plan will have significant implications for the company's future growth and profitability.